68Ga-PSMA in PC
Research type
Research Study
Full title
Feasibility study of 68Ga-PSMA PET/CT as a non-invasive marker of nodal status in low , intermediate and high risk prostate cancer and correlation with prostate specific membrane antigen expression.
IRAS ID
196363
Contact name
Tara Barwick
Contact email
Sponsor organisation
Imperial college, London
Duration of Study in the UK
1 years, 6 months, 30 days
Research summary
Pelvic node involvement is a major prognostic factor in prostate cancer. There is a clinical need for accurate non-invasive nodal staging for prostate cancer in order to plan optimum treatment (surgical or non surgical). Clinical markers encorporating the serum PSA level, Gleason score and digital rectal examination findings can predict prognosis and the risk of nodal involvement in a patient group but accurate non invasive nodal staging is essential for making individual therapeutic decisions. Conventional CT and MRI which rely on morphological and size criteria are limited. FDG PET/CT imaging has been disappointing in prostate cancer patients as even aggressive tumours may have low level glucose metabolism
Prostate specific membrane antigen (PSMA) is a protein that shows significant overexpression on prostate cancer cells. PSMA antigen expression levels have been shown to increase with stage and grade of tumour. No study has explored the correlation of Ga 68 PSMA uptake in PET with PSMA antigen expression in tissue in the clinical setting.This prospective observational study aims to assess Ga68 PSMA PET/CT in low-risk, intermediate and high risk prostate cancer patients and correlate with PSMA antigen expression in tissue. In addition the detection of nodal involvement shall be assessed and uptake will be correlated with other tissues markers (Ki-67 and hK2 expression).REC name
North of Scotland Research Ethics Committee 1
REC reference
16/NS/0032
Date of REC Opinion
7 Apr 2016
REC opinion
Further Information Favourable Opinion